Prostate Cancer Diagnostics Industry Best Market Trends and Useful Forecast Estimation till 2022

Rockville, US, 2018-Jan-29 — /EPR Network/ — Uncontrollable growth of cells in prostate gland leads to the development of prostate cancer. Several men develop low-grade prostatic intraepithelial neoplasia (PIN), however they don’t necessarily develop prostate cancer. No sure way has been found to prevent prostate cancer, however the chances can be lowered by being physically active and maintaining a healthy weight.

Request For Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=58

5 Estimations from Fact.MR’s Report on the Global Prostate Cancer Diagnostics Market

1. North America will continue to be the most lucrative region in the global prostate cancer diagnostics market, in terms of revenues. The prostate cancer diagnostics market in North America and Europe are expected to exhibit similar CAGRs through 2022.
2. The market in Asia-Pacific excluding Japan (APEJ) is expected to register the fastest expansion through 2022. In contrast, prostate cancer diagnostics market in Middle East & Africa will continue to register a sluggish expansion during the forecast period.
3. PSA tests will continue to be the largest adopted tests for diagnosis of prostate cancer across the globe. PSA test segment is projected to register the highest CAGR in the market through 2022.
4. Hospital-associated labs are expected to remain the largest end-users of prostate cancer diagnostics in the global market, however revenues from prostate cancer diagnostics in hospital-associated labs will register the lowest CAGR in the market through 2022.
5. In terms of revenues, cancer research institutes are expected to register the highest CAGR in the market through 2022. Independent diagnostics labs will remain the second largest end users of the prostate cancer diagnostics during the forecast period.

Browse Full Report with TOC @ https://www.factmr.com/report/58/prostate-cancer-diagnostics-market

Smaller Share of CTC

The CTC segment holds revenue share in the global prostate cancer diagnostics market. This segment is projected to reach US$ 141 million by the end of 2022.

The immunohistochemistry segment is projected to witness a CAGR of 4.5% for the five-year study period. While North America may be the largest regional contributor, key stakeholders could also focus on Europe as it holds a revenue share of more than 30% throughout the period.

Focus on Hospital Labs and Research Institutes

The hospital associated labs segment is assessed to grow significantly during the forecast period. It would make sense for companies to focus on cancer research institutes as collaboration can help in the development of innovative solutions. In this case, companies could think of targeting the APEJ region as it has the highest CAGR during the forecast period. The region spends much less on healthcare as a percentage of GDP than the developed world but strong economic growth will all but ensure that it becomes ever-more important to regional governments in future.

Competition Tracking

Key players in the global market for prostate cancer diagnostics include Abbott Laboratories, Biocept, Inc., AstraZeneca plc., Cancer Genetics, Inc., Danaher Corporation, Bayer Aktiengesellschaft, Becton, Dickinson and Company, Agilent Technologies, Foundation Medicine, Inc., and Myriad Genetics Inc.

Check Discount @ https://www.factmr.com/connectus/sample?flag=D&rep_id=58

About Fact.MR       
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us               
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/